Jazz Pharmaceuticals

We’re a global biopharma company developing life-changing medicines for people with rare disease. Please see our social guidelines -

[Jazz Pharmaceuticals @JazzPharma]

Our official Twitter account for information and updates from Jazz Pharmaceuticals is @JazzPharma.

[Jazz Pharmaceuticals @JazzPharma]

#News for U.S. media and investors: The U.S. FDA has approved our HER2-targeted therapy as part of two first-line treatment regimens for adults with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). Learn more: https://t.co/5AWDwr3lYs

[Jazz Pharmaceuticals @JazzPharma]

We're pleased to announce a definitive agreement to acquire Actio Biosciences, adding to our #epilepsy portfolio and reinforcing our commitment to bringing meaningful treatments to people living with rare diseases. Subject to customary closing conditions. https://t.co/sjvLW8OcKz

[Jazz Pharmaceuticals @JazzPharma]

Our Q2 2026 results reflect strong execution, continued momentum, and progress against our long-term growth strategy. Explore our Q2 results: https://t.co/Wopoh0kFAn

[Jazz Pharmaceuticals @JazzPharma]

We’re proud to share our 2025 Corporate Sustainability and Social Impact (CSSI) Report. It reflects how we’re advancing our purpose, delivering impact and building trust with key stakeholders. Read more: https://t.co/PdPVV1dzFK

[Jazz Pharmaceuticals @JazzPharma]

#News for U.S. media and investors:  We’re pleased to announce a pre-clinical research collaboration and option-to-license agreement with @AbCelleraBio to discover and develop next-generation T-cell engaging (TCE) multispecific antibodies for GI cancers: https://t.co/KxKw0E5m3u

[Jazz Pharmaceuticals @JazzPharma]

#News for U.S. media and investors: At #SLEEP2026 we’re presenting 11 late-breaking data presentations, advancing understanding for rare sleep disorders. Learn more: https://t.co/yCaoTf0R52

[Jazz Pharmaceuticals @JazzPharma]

We are excited to be on the ground at #SLEEP2026 this week, where we are connecting with fellow leaders in the sleep community, like @American_Heart, to share more on the critical connection between sleep, sodium intake and hypertension. Learn more below.

[AHA Science @AHAScience]

Stop by Booth 832 to learn more about how sleep and sodium intersect in managing hypertension and overall health. #SLEEP2026

🗓️ June 14-17
📍Baltimore Convention Center

Jazz Pharmaceuticals, Inc. is proud to support the American Heart Association’s Hypertension, Sodium and Sleep Professional Education Initiative.

[Jazz Pharmaceuticals @JazzPharma]

Global Head of R&D and Chief Medical Officer Rob Iannone sat down with @FiercePharma to discuss the evolving HER2-targeted treatment landscape and Jazz’s strategic focus in HER2 to help address unmet needs for patients. Watch the full interview: https://t.co/Gcsjg7Yh9Q

[Jazz Pharmaceuticals @JazzPharma]

#News for U.S. media and investors: We are proud to attend #SLEEP2026 and present research on rare sleep disorders. Learn more about our data: https://t.co/xi18PCNeyq

[Jazz Pharmaceuticals @JazzPharma]

As we kick off #ASCO26, we’re excited to be presenting on Monday additional subgroup analyses from our Phase 3 trial in HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). Learn more about the results, recently published in @NEJM: https://t.co/UTjObtOKLg

[Jazz Pharmaceuticals @JazzPharma]

We are joining the global cancer research community at #ASCO26 this weekend. With three rapid oral presentations and additional posters, we’re sharing data from across our oncology portfolio that reflect our ongoing efforts in some of the most difficult-to-treat cancers.

[Jazz Pharmaceuticals @JazzPharma]

#News for U.S. media and investors: @NEJM has published our Phase 3 results for HER2+ gastroesophageal adenocarcinoma (GEA), representing potential hope for patients with this rare disease who have historically faced limited long-term options. Learn more: https://t.co/UTjObtOKLg

[Jazz Pharmaceuticals @JazzPharma]

#News for U.S. media and investors: Jazz announces first quarter 2026 financial results $JAZZ: https://t.co/zSqgGuSpc0

[Jazz Pharmaceuticals @JazzPharma]

#News for U.S. media and investors: Today, the U.S. FDA accepted and granted Priority Review for the supplemental Biologic License Application (sBLA) for our potential treatment for HER2+ unresectable locally advanced or metastatic GEA. Learn more: https://t.co/lvDZkjfqSD

[Jazz Pharmaceuticals @JazzPharma]

#News for U.S. media and investors: At #ASCO26, we’ll be sharing data that highlights continued momentum across our oncology portfolio, including gastroesophageal adenocarcinoma and small cell lung cancer. Learn more here: https://t.co/6Y1KRqDxk0

[Jazz Pharmaceuticals @JazzPharma]

#News for U.S. media and investors: We’re at the @AANMember Annual Meeting, sharing data reinforcing our commitment to advancing options for people with rare neurological disorders. Learn more about our #AANAM data here: https://t.co/VwxEkq2cTK

[Jazz Pharmaceuticals @JazzPharma]

#News for U.S. media and investors: At #AACR26, we’ll be sharing new clinical and pre-clinical research that highlights meaningful progress across our oncology portfolio, including Phase 2 results in early-stage HER2+ breast cancer. Learn more here: https://t.co/egNui4U2CK

[Jazz Pharmaceuticals @JazzPharma]

We’re excited to welcome George Eliades back to Jazz as our Chief Transformation Officer. His experience and leadership will help sharpen our focus, strengthen execution, and accelerate our impact for patients and their families.

[Jazz Pharmaceuticals @JazzPharma]

#News for U.S. media and investors: Jazz announces fourth quarter and full year 2025 financial results $JAZZ: https://t.co/RX7Qz6jS88

[Jazz Pharmaceuticals @JazzPharma]

U.S. Oncology Franchise Head Chumi Khurana shares her perspective in @FiercePharma on why the first-line setting matters in metastatic HER2+ gastroesophageal adenocarcinoma (GEA), where improving survival outcomes remains a key need. Read more: https://t.co/HgeegPPk3X